Impact of baseline PD-L1 status in BCG naive nonmuscle invasive bladder cancer on outcomes and changes after BCG exposure

This publication has 21 references indexed in Scilit:

• Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients
  Urologic Oncology: Seminars and Original Investigations, 2023
• Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up
  Annals of Oncology, 2022
• A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-Guérin-exposed Non–muscle-invasive Bladder Cancer
  European Urology, 2022
• PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment
  World Journal of Urology, 2020
• Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC)
  World Journal of Urology, 2019
• Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications
  Journal of Urology, 2017
• Immunotherapy for the Treatment of Urothelial Carcinoma
  Journal of Urology, 2017
• Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model
  Journal of Urology, 2009
• PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata
  Cancer, 2007
• Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers
  Cancer Immunology, Immunotherapy, 2006